Findings

What do systematic reviews say?

52 questions · 52 findings · 5 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 8 · 15.4%GRADE not reported 0 · 0%Very low 4 · 7.7%Low 6 · 11.5%Moderate 17 · 32.7%High 17 · 32.7%

Intervention not reported

CIN3+ associated with HPV16/18 · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination

The intervention leads to lower CIN3+ associated with HPV16/18 (high certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.01 [0, 0.1]
2 studies · 20214 participants
High

Intervention not reported

Babies born with congenital malformations · adolescent girls and women aged 15 to 45 years who became pregnant during the study

The intervention showed no clear difference in babies born with congenital malformations (moderate certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 1.22 [0.88, 1.69]
5 studies · 9252 participants
Moderate

Intervention not reported

AIS associated with HPV16/18 · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination

The intervention probably leads to lower AIS associated with HPV16/18 (moderate certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.1 [0.01, 0.82]
2 studies · 20214 participants
Moderate

Intervention not reported

Any CIN2+ irrespective of HPV type, bivalent or quadrivalent vaccine · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination

The intervention leads to lower any CIN2+ irrespective of HPV type, bivalent or quadrivalent vaccine (high certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.37 [0.25, 0.55]
5 studies · 25180 participants
High

Intervention not reported

Any CIN2+ irrespective of HPV type · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination

The intervention leads to lower any CIN2+ irrespective of HPV type (high certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.33 [0.25, 0.43]
4 studies · 15884 participants
High

Intervention not reported

Any CIN3+ irrespective of HPV type, bivalent or quadrivalent vaccine · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination

The intervention showed no clear difference in any CIN3+ irrespective of HPV type, bivalent or quadrivalent vaccine (moderate certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.21 [0.04, 1.1]
3 studies · 20719 participants
Moderate

Intervention not reported

Any CIN3+ irrespective of HPV type · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination

The intervention leads to lower any CIN3+ irrespective of HPV type (high certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.08 [0.03, 0.23]
2 studies · 11423 participants
High

Intervention not reported

Any AIS irrespective of HPV type · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination

The intervention probably leads to lower any AIS irrespective of HPV type (moderate certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.1 [0.01, 0.76]
2 studies · 20214 participants
Moderate

Intervention not reported

Incidence of GTN (including low‐quality studies) · women with a molar pregnancy

The intervention may leads to lower incidence of GTN (including low‐quality studies) (low certainty).

1 finding from 1 review

Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia 2017 · Cochrane Headline outcomes only
RR 0.37 [0.24, 0.57]
3 studies · 550 participants
Low

Intervention not reported

Incidence of GTN (excluding low‐quality studies) · women with a molar pregnancy

The intervention may leads to lower incidence of GTN (excluding low‐quality studies) (low certainty).

1 finding from 1 review

Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia 2017 · Cochrane Headline outcomes only
RR 0.28 [0.1, 0.73]
1 study · 59 participants
Low

Intervention not reported

Time to GTN diagnosis (days) · women with a molar pregnancy

The intervention may leads to higher time to GTN diagnosis (days) (low certainty).

1 finding from 1 review

Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia 2017 · Cochrane Headline outcomes only
MD 28.72 [13.19, 44.24]
2 studies · 33 participants
Low

Intervention not reported

Number of courses of chemotherapy to cure · women with a molar pregnancy

It is very uncertain whether the intervention changes number of courses of chemotherapy to cure (very low certainty).

1 finding from 1 review

Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia 2017 · Cochrane Headline outcomes only
MD 1.1 [0.52, 1.68]
1 study · 14 participants
Very low